The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation.
Bone metastases
KRAS mutation
bisphosphonate therapy
lung adenocarcinoma (LADC)
radiation therapy
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
KRAS mutation is the most common genetic alteration in lung adenocarcinoma (LADC) in Western countries and is associated with worse outcome in bone-metastatic cases. Yet, to date, no effective treatment guidelines were developed for these patients. Accordingly, our aim was to investigate the impact of KRAS mutation on bisphosphonate (BTx) and radiation therapy (RTx) in bone-metastatic LADC patients. Clinicopathological variables of 134 consecutive LADC patients with bone metastases at diagnosis and known KRAS status were retrospectively analyzed. The effects of BTx, RTx and KRAS mutation on overall survival (OS) were investigated. Of the total cohort, 93 patients were identified as KRAS wild-type (WT) (69.4%) and 41 (30.6%) as KRAS mutant patients. The presence of KRAS mutation was associated with significantly reduced median OS (5.1 KRAS mutation is a strong negative prognostic factor in bone-metastatic LADC patients. Both BTx and RTx can increase the OS with a pronounced benefit for patients with KRAS WT tumors. Altogether, KRAS mutational status should be considered during therapeutic decision making in bone-metastatic LADC patients.
Sections du résumé
BACKGROUND
BACKGROUND
KRAS mutation is the most common genetic alteration in lung adenocarcinoma (LADC) in Western countries and is associated with worse outcome in bone-metastatic cases. Yet, to date, no effective treatment guidelines were developed for these patients. Accordingly, our aim was to investigate the impact of KRAS mutation on bisphosphonate (BTx) and radiation therapy (RTx) in bone-metastatic LADC patients.
METHODS
METHODS
Clinicopathological variables of 134 consecutive LADC patients with bone metastases at diagnosis and known KRAS status were retrospectively analyzed. The effects of BTx, RTx and KRAS mutation on overall survival (OS) were investigated.
RESULTS
RESULTS
Of the total cohort, 93 patients were identified as KRAS wild-type (WT) (69.4%) and 41 (30.6%) as KRAS mutant patients. The presence of KRAS mutation was associated with significantly reduced median OS (5.1
CONCLUSIONS
CONCLUSIONS
KRAS mutation is a strong negative prognostic factor in bone-metastatic LADC patients. Both BTx and RTx can increase the OS with a pronounced benefit for patients with KRAS WT tumors. Altogether, KRAS mutational status should be considered during therapeutic decision making in bone-metastatic LADC patients.
Identifiants
pubmed: 33718013
doi: 10.21037/tlcr-20-754
pii: tlcr-10-02-675
pmc: PMC7947398
doi:
Types de publication
Journal Article
Langues
eng
Pagination
675-684Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-754). The authors have no conflicts of interest to declare.
Références
World J Clin Oncol. 2014 Dec 10;5(5):845-57
pubmed: 25493222
Breast Cancer Res. 2006;8(4):R52
pubmed: 16925824
Sci Rep. 2017 Aug 21;7(1):8970
pubmed: 28827719
Ann Transl Med. 2017 Sep;5(17):353
pubmed: 28936447
Oncotarget. 2017 Apr 11;8(15):25691-25699
pubmed: 28148890
Radiat Oncol. 2019 Jan 18;14(1):13
pubmed: 30658673
Cancer. 2003 Feb 1;97(3 Suppl):840-7
pubmed: 12548584
Eur J Cancer. 2014 Jul;50(10):1819-1828
pubmed: 24768329
Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s41-s46
pubmed: 29700092
J Clin Oncol. 2013 Mar 10;31(8):1112-21
pubmed: 23401440
Radiother Oncol. 1988 Jan;11(1):31-53
pubmed: 3278340
Anticancer Res. 2010 Jul;30(7):2713-20
pubmed: 20683003
Support Care Cancer. 2012 Nov;20(11):2985-98
pubmed: 22956190
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):535-42
pubmed: 15667977
Sci Rep. 2017 Jan 04;7:39721
pubmed: 28051122
Pathol Oncol Res. 2015 Sep;21(4):1217-21
pubmed: 26055897
Br J Cancer. 2005 Jan 17;92(1):131-9
pubmed: 15597105
Eur Radiol. 2020 Sep;30(9):5021-5028
pubmed: 32323012
J Clin Oncol. 2013 Jun 10;31(17):2173-81
pubmed: 23630215
J Thorac Oncol. 2009 Feb;4(2):251-9
pubmed: 19179905
BMJ Open. 2014 Jul 24;4(7):e005202
pubmed: 25059970
Oncology. 2016;90(2):103-11
pubmed: 26785048
J Thorac Oncol. 2008 Feb;3(2):125-9
pubmed: 18303431
Lung Cancer. 2018 Dec;126:139-148
pubmed: 30527178
Ther Adv Med Oncol. 2014 May;6(3):101-14
pubmed: 24790650
Br J Cancer. 2003 Jun 16;88(12):1971-8
pubmed: 12799645
N Engl J Med. 1990 Aug 30;323(9):561-5
pubmed: 2199829
Cancer Res. 1991 Sep 15;51(18):4999-5002
pubmed: 1654209
BMC Cancer. 2019 Apr 3;19(1):303
pubmed: 30943924
J Clin Invest. 1994 Feb;93(2):516-20
pubmed: 7906694
Lung Cancer. 2018 Jul;121:76-81
pubmed: 29858031
Cancer Treat Rev. 2003 Aug;29(4):321-7
pubmed: 12927572
Cell Prolif. 2011 Apr;44(2):139-46
pubmed: 21401755
Lung Cancer. 2005 Nov;50(2):271-2
pubmed: 16112774
World J Radiol. 2012 Apr 28;4(4):128-34
pubmed: 22590666
Oncol Lett. 2019 Mar;17(3):3233-3240
pubmed: 30867754
Front Oncol. 2019 Sep 25;9:953
pubmed: 31612108
Oncotarget. 2016 Nov 29;7(48):79503-79514
pubmed: 27780929
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Curr Opin Oncol. 2014 Mar;26(2):138-44
pubmed: 24463346
Br J Cancer. 2000 Apr;82(8):1459-68
pubmed: 10780527
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472
pubmed: 31805526
Oral Oncol. 2011 Jun;47(6):487-96
pubmed: 21498106
Cancer Res. 2001 Mar 15;61(6):2602-8
pubmed: 11289137
Lung Cancer. 2018 Oct;124:53-64
pubmed: 30268480
Carcinogenesis. 1999 Aug;20(8):1507-10
pubmed: 10426799
Bonekey Rep. 2014 Oct 01;3:580
pubmed: 25328676
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711